Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3952W HIGH $15.88
Volume
113.88 K
Value Traded
59.71 M
Short % Float
29.58%
-4.09%Week
-19.28%1 Month
-11.76%3 Month
+136.55%6 Month
-18.62%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.30 B
EPS (TTM)
-0.16
P/E Ratio
-
Ent. Value
2.14 B
Total Shares
201.93 M
Float Shares
199.70 M
Insiders
1.11%
Institutions
36.73%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SLS Catalyst Timeline
Dated clinical, regulatory and corporate events for SELLAS Life Sciences Group, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for SELLAS Life Sciences Group, Inc.
874Total events
3Upcoming
188Tier-1 (high impact)
2011 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationSLS009Presentation
Poster A036: Elucidating MYC allelic imbalance and therapeutic response in PDAC via patient-derived organoids
pancreatic ductal adenocarcinomasource ↗
▲Preclinical PoCSLS009Preclinical
SLS009 preclinical data in MYC-amplified, daraxonrasib-resistant PDAC organoid models presented at AACR
pancreatic ductal adenocarcinomasource ↗
◆Oral PresentationPresentation
TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
◆Enrollment UpdateGalinpepimut-STrial
78 events occurred in REGAL trial as of May 11, 2026
Acute Myeloid Leukemiasource ↗
◆Enrollment MilestoneGalinpepimut-STrial
78 events occurred in REGAL trial as of May 11, 2026
Acute Myeloid Leukemia (AML)source ↗
▲First Patient DosedSLS009Trial
First patient dosed in Phase 2 trial of SLS009 in newly diagnosed first-line AML
Acute Myeloid Leukemia (AML)source ↗
◆Poster PresentationSLS009Presentation
Poster presentation of preclinical data on SLS009 in AML at AACR 2026
acute myeloid leukemia (AML)source ↗
◆Trial InitiationSLS009Trial
Enrollment initiation at European sites for SLS009 in combination with AZA/VEN in frontline AML
newly diagnosed AML with high-risk featuressource ↗
●Enrollment MilestoneSLS009Trial
Enrollment of approximately 40 patients in Europe anticipated in Q2 2026
newly diagnosed AMLsource ↗
▲First Patient DosedSLS009Trial
First patient dosed in Phase 2 trial of SLS009 in newly diagnosed first-line AML
newly diagnosed first-line AMLsource ↗
▲First Patient DosedSLS009Trial
First patient enrolled in Phase 2 trial of SLS009 in newly diagnosed first-line AML
acute myeloid leukemiasource ↗
▲Full ResultsSLS009Clinical Data
Positive Phase 2 results in r/r AML reported
relapsed/refractory acute myeloid leukemiasource ↗
▲Partnership / LicenseSLS009Corporate
Agreement with IMPACT-AML to expand SLS009 clinical program into Europe
acute myeloid leukemia (AML)source ↗
◆Trial InitiationSLS009Trial
Newly diagnosed and frontline AML study anticipated to begin in Q1 2026
acute myeloid leukemiasource ↗
▲Poster PresentationSLS009Presentation
Preclinical data on SLS009 presented at AACR 2026
Acute Myeloid Leukemiasource ↗
▲Equity OfferingCorporate
Received additional $42.6 million in proceeds from warrant exercises in Q1 2026
▲Partnership / LicenseSLS009Corporate
Strategic collaboration with IMPACT-AML to expand SLS009 clinical program in Europe
AMLsource ↗
●Enrollment UpdateGalinpepimut-STrial
Pooled number of events at 72 as of December 26, 2025
Acute Myeloid Leukemiasource ↗
▲Oral PresentationSLS009Presentation
Phase 2 data of SLS009 in combination with AZA/VEN presented at ASH 2025
relapsed/refractory AML with MDS-related changes (AML-MR)source ↗
◆Poster PresentationSLS009Presentation
Phase 2 data of SLS009 in combination with azacitidine and venetoclax in r/r AML-MR presented at ASH 2025
relapsed/refractory acute myeloid leukemia with MDS-related changessource ↗
◆Oral PresentationSLS009Presentation
Phase 2 data for SLS009 in R/R AML accepted for presentation at ASH 2025
relapsed or refractory acute myeloid leukemiasource ↗
●PublicationSLS009Presentation
Preclinical abstract published on ASH website and in Blood describing mechanism of action of SLS009 in AML cell lines
acute myeloid leukemiasource ↗
◆R&D DayPresentation
Virtual R&D Day on AML, GPS Phase 3 REGAL trial, and SLS009 program update
acute myeloid leukemiasource ↗
●R&D DayGalinpepimut-SPresentation
SELLAS Life Sciences Virtual R&D Day
Acute Myeloid Leukemiasource ↗
◆Poster PresentationSLS009Presentation
Poster presentation of preclinical data for SLS009 in T-PLL at ESMO 2025
T-cell prolymphocytic leukemiasource ↗
▲Oral PresentationSLS009Presentation
Preclinical data on SLS009 in T-PLL presented at ESMO 2025
T-cell prolymphocytic leukemiasource ↗
▲Equity OfferingCorporate
Received $54.6 million gross proceeds from warrant exercises in September and October 2025
◆Poster PresentationSLS009Presentation
Preclinical efficacy of SLS009 in T-PLL to be showcased at ESMO 2025
T-Cell Prolymphocytic Leukemia (T-PLL)source ↗
▲Primary Endpoint MetSLS009Clinical Data
Phase 2 trial of SLS009 in r/r AML met all primary endpoints
Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)source ↗
▲End Of Phase 2 MeetingSLS009FDA Meeting
End-of-Phase 2 meeting with FDA for SLS009 in AML
Acute Myeloid Leukemia (AML)source ↗
▲DSMB ReviewGalinpepimut-STrial
IDMC periodic review and positive recommendation to continue REGAL trial without modification
acute myeloid leukemiasource ↗
▲DSMB ReviewGalinpepimut-STrial
IDMC recommends REGAL trial continue without modification
Acute Myeloid Leukemiasource ↗
▲Primary Endpoint MetSLS009Clinical Data
Phase 2 trial of SLS009 met all primary endpoints in r/r AML
relapsed/refractory acute myeloid leukemia (r/r AML)source ↗
▲FDA Feedback ReceivedSLS009FDA Meeting
FDA guidance received to advance SLS009 into first-line therapy study
acute myeloid leukemia (AML)source ↗
▲Equity OfferingCorporate
Received $4.0 million in proceeds from warrant exercises in July 2025
◆Poster PresentationSLS009Presentation
Poster presentation of in vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines at ASCO 2025
ASXL1 mutated colorectal cancersource ↗
▲Preclinical PoCSLS009Preclinical
Preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer presented at ASCO 2025
ASXL1 mutated colorectal cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How SLS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-27 | SLS009 (tambiciclib) | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$855M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 23%
Small Cap(rank 152 of 658)
Percentile Rank
SELLAS Life Sciences Group, Inc. carries a moderate pipeline score (48/100), with $1.3B risk-adjusted pipeline value, led by NeuVax vaccine in Breast Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NeuVax vaccine VaccineCompletedNCT01570036 | Breast Cancer | Phase 2 | COMPLETED | 375 | Sep 28, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every SLS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kalin Katherine BachDirector | Buy | 63,400 104,400 held | $1.59 | 11/19/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in SLS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0.3 % | 22.14 M | 1.50 M |
SLS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLS ranks across every disease it competes in
Competitive Position is a premium feature
See how SLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLS News
SLSSELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences presented preclinical data on SLS009, a CDK9 inhibitor, at the AACR Conference. The data indicated that SLS009 significantly increased apoptosis in pancreatic cancer models resistant to daraxonrasib. Additionally, combining SLS009 with daraxonrasib and BET inhibitors showed promising synergistic effects, suggesting potential strategies for overcoming resistance in MYC-driven pancreatic cancer.
Read more →SLS▲ +7.1%on this news
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
SELLAS Life Sciences announced that three abstracts on SLS009, a CDK9 inhibitor, have been accepted for presentation at the AACR Conference on Pancreatic Cancer. The studies focus on its preclinical activity in pancreatic ductal adenocarcinoma using patient-derived organoid models. The conference will take place from September 25-28, 2026, in San Diego, CA.
Read more →SLS▲ +6.5%on this news· ran to +18% by day 3
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its financial results for Q2 2026, highlighting significant progress in its clinical programs, including the Phase 3 REGAL trial for GPS in AML and ongoing trials for SLS009. The company has enrolled 28 patients in the Phase 2 trial for SLS009, with topline data expected in Q4 2026. Despite a net loss increase, SELLAS maintains a strong cash position of $138.3 million.
Read more →SLS▲ +13.6%on this news
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
SELLAS Life Sciences Group, Inc. has announced participation in several upcoming investor conferences, including the Stifel Virtual Targeted Oncology Forum and A.G.P.'s Annual Virtual Healthcare Conference. CEO Angelos Stergiou will represent the company at these events, highlighting SELLAS's focus on developing novel cancer therapies, including their lead product GPS and the small molecule CDK9 inhibitor SLS009.
Read more →SLS▲ +25.1%on this news· ran to +42% by day 1shared move
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its Q1 2026 financial results, highlighting the ongoing Phase 3 REGAL trial of Galinpepimut-S (GPS) in AML, with 78 events recorded so far. The company is also advancing its Phase 2 trial of SLS009, targeting high-risk AML patients. Despite a net loss increase, SELLAS maintains a strong cash position of $107.1 million.
Read more →SLS▼ -8.5%on this news
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its financial results for 2025, highlighting significant advancements in its clinical programs for acute myeloid leukemia (AML). The company is nearing the final analysis of its Phase 3 REGAL trial for GPS and has initiated a Phase 2 trial for SLS009. With a strong cash position and positive trial results, SELLAS aims to expand its treatment options in AML. However, it also faces challenges, including a reported net loss and the uncertainty of trial outcomes.
Read more →SLS▼ -6%on this newsshared move
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
SELLAS Life Sciences announced that preclinical data for its CDK9 inhibitor SLS009 will be presented at the AACR conference in April 2026. The data show that SLS009 significantly increases apoptosis in acute myeloid leukemia (AML) cells and is especially effective against mutations that typically indicate poor prognosis. Initial results suggest that the drug may be a powerful treatment option across different genetic backgrounds of AML. The presentation will take place on April 21, 2026, and aims to highlight the clinical potential of SLS009.
Read more →SLS▼ -8.2%on this newsshared move
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
SELLAS Life Sciences has enrolled the first patient in its Phase 2 trial for SLS009, a CDK9 inhibitor targeting newly diagnosed acute myeloid leukemia (AML) patients. The study aims to enroll 80 patients, focusing on those unlikely to benefit from standard therapies. Topline data is expected by Q4 2026, following promising results in relapsed/refractory AML.
Read more →SLS▼ -6.6%on this news
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
SELLAS Life Sciences has partnered with IMPACT-AML to advance the SLS009 clinical program in Europe. This collaboration will facilitate a clinical study evaluating SLS009, a CDK9 inhibitor, across multiple European sites. The study aims to enroll around 40 patients with newly diagnosed AML, enhancing patient access and participation in the clinical program.
Read more →SLS▲ +16.7%on this news· ran to +52% by day 3
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
SELLAS Life Sciences provided an update on its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukemia (AML). The trial continues following a recommendation from the Independent Data Monitoring Committee, with 72 of the required 80 events reported. The company remains blinded to efficacy data and will announce the final analysis upon reaching the event threshold.
Read more →SLSSELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
SELLAS Life Sciences presented positive Phase 2 data for SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for relapsed/refractory acute myeloid leukemia with myelodysplastic syndrome-related changes. The study showed a 46% overall response rate among 35 evaluable patients, with median overall survival exceeding expectations. The combination was well tolerated with no dose-limiting toxicities.
Read more →SLSSELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its Q3 2025 financial results, highlighting positive developments in its AML-focused pipeline. The Phase 2 data for SLS009 has been accepted for presentation at the ASH Annual Meeting, and plans for a new trial in first-line AML patients are underway. The company has a solid cash position following recent warrant exercises, positioning it for growth.
Read more →SLSSELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
SELLAS Life Sciences announced that data from its Phase 2 study of SLS009 will be presented at the 2025 ASH Annual Meeting. The study evaluates SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for patients with relapsed/refractory AML. The presentation aims to showcase the potential of SLS009 in addressing difficult-to-treat cancers.
Read more →SLSSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
SELLAS Life Sciences Group announced the exercise of existing warrants, generating approximately $31 million in gross proceeds. The investor will receive new warrants for the same number of shares at an exercise price of $2.00. The transaction is expected to close on October 28, 2025. Additionally, SELLAS will host a virtual R&D Day to discuss acute myeloid leukemia treatment advancements.
Read more →SLSSELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
SELLAS Life Sciences Group, Inc. announced that its CEO, Dr. Angelos Stergiou, will participate in the J.P. Morgan U.S. Opportunities Forum on November 12, 2025. The event will take place at the Kimpton EPIC Hotel in Miami, Florida, and will feature one-on-one investor meetings. SELLAS is advancing its lead product candidate, GPS, and developing SLS009, a CDK9 inhibitor.
Read more →SLSSELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
SELLAS Life Sciences announced that preclinical data for SLS009, a CDK9 inhibitor, will be presented at the ESMO Congress 2025. The study shows that SLS009, both alone and in combination with venetoclax, significantly prolongs survival in T-cell prolymphocytic leukemia compared to venetoclax alone. The findings suggest SLS009 could be a critical treatment option for this aggressive leukemia.
Read more →SLSSELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
SELLAS Life Sciences Group will host a virtual R&D Day on October 29, 2025, to discuss advancements in acute myeloid leukemia (AML) therapies. The event will feature insights on the ongoing Phase 3 REGAL trial of Galinpepimut-S (GPS) and updates on the SLS009 program. Key opinion leaders will address the unmet needs in AML treatment and present recent Phase 2 data for SLS009.
Read more →About SELLAS Life Sciences Group, Inc.
Headquarters7 TIMES SQUARE, NEW YORK, NY, 10036
BIOPHARMAWATCH ELITE PLUS
Trade the next SLS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime